Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. Approved in the European Union, it treats chronic myeloid leukemia in patients who are Philadelphia chromosome‑positive.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing for oncology therapeutics with a focus on quality assurance and regulatory compliance.

Nilotinib is used in the management of chronic myeloid leukemia, targeting BCR‑ABL driven disease.

- Chronic Myeloid Leukemia (chronic phase): reduces disease progression, achieves deep molecular responses, and improves long‑term survival. - Accelerated Phase CML: induces hematologic remission and cytogenetic response, helping to control rapidly proliferating leukemic cells. - Imatinib‑resistant CML: offers an effective alternative by targeting BCR‑ABL mutations that diminish imatinib efficacy.

Nilotinib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Rash: skin erythema or pruritic lesions. - Elevated serum lipase/amylase: mild pancreatic enzyme increase.

Serious or Rare Side Effects: - Cardiovascular events: arterial occlusive disease, myocardial infarction, or stroke. - Hepatotoxicity: significant elevation of liver transaminases or bilirubin. - Pancreatitis: acute inflammation of the pancreas requiring medical attention.

When prescribing Nilotinib, clinicians should consider several precautionary measures to ensure safe use.

- Cardiac assessment: evaluate history of arterial disease before initiating therapy. - Hepatic monitoring: perform baseline liver function tests and repeat periodically. - Electrolyte balance: monitor serum potassium and magnesium, correcting abnormalities. - QT interval: obtain ECG and avoid concurrent QT‑prolonging drugs. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women; discuss contraception. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Nilotinib interacts with several medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Nilotinib exposure. - Antacids containing aluminum or magnesium: decrease absorption if taken concurrently. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib plasma levels. - Proton pump inhibitors: can modestly affect gastric pH and drug absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for increased statin exposure and muscle toxicity.